RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS

RenovoRx (NASDAQ:RNXT) released its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02, FiscalAI reports. RenovoRx had a negative net margin of 823.98% and a negative return on equity of 135.03%.

Here are the key takeaways from RenovoRx’s conference call:

• Record revenue and upgraded guidance: Second-quarter revenue rose 61% sequentially and 115% year over year to $909,000, prompting RenovoRx to raise 2026 revenue guidance to $3.75 million–$4.25 million from $3 million–$4 million.
• Commercial expansion is accelerating: Active commercial cancer centers increased from 16 to 21 during the quarter, with 42 additional centers in the pipeline and a target of at least 36 active centers by year-end. Management said repeat orders and site conversions from the TIGeR-PaC trial should support another record revenue quarter in Q3.
• Clinical and product opportunity expanded: RenovoCath was used commercially for the first time in a sarcoma patient, providing physician-driven evidence of potential applications beyond locally advanced pancreatic cancer. Management also cited supportive clinical publications and growing physician advocacy.
• Phase III trial enrollment completed: The TIGeR-PaC study is nearly fully randomized, with 78 of the required 86 events reported as of August 11, 2026. Trial completion is expected in the first half of 2027, with initial topline data anticipated in the second half of 2027.
• Company remains loss-making and cash-constrained: RenovoRx reported a $3.4 million operating loss and held $9.5 million in cash at quarter-end. Although management expects cash to fund operations into the second half of 2027 and projects cash-flow break-even in Q4 2027, further capital could be needed if growth or trial timelines fall short.

RenovoRx Stock Down 2.6%

RenovoRx stock traded down $0.03 during midday trading on Wednesday, hitting $1.12. 460,263 shares of the stock were exchanged, compared to its average volume of 310,216. RenovoRx has a 52-week low of $0.70 and a 52-week high of $1.45. The business’s 50-day moving average price is $0.94 and its 200-day moving average price is $0.93. The stock has a market capitalization of $50.46 million, a price-to-earnings ratio of -3.39 and a beta of 0.99.

Hedge Funds Weigh In On RenovoRx

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bleichroeder LP lifted its holdings in RenovoRx by 11.4% during the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after acquiring an additional 61,379 shares during the period. Geode Capital Management LLC increased its position in shares of RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after purchasing an additional 31,730 shares during the last quarter. Wealthspire Advisors LLC bought a new stake in shares of RenovoRx during the 4th quarter worth $212,000. Citadel Advisors LLC bought a new stake in shares of RenovoRx during the 3rd quarter worth $154,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of RenovoRx in the 2nd quarter worth about $98,000. Hedge funds and other institutional investors own 3.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on RNXT. Wall Street Zen raised shares of RenovoRx from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 17th. Finally, Ascendiant Capital Markets upped their target price on shares of RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, RenovoRx currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.